Potential utility of <i>FGFR2</i> mutation status as an adverse prognostic factor to affect clinical decision-making.

<p>The decision tree is adapted from 2011 National Comprehensive Cancer Network guidelines using FIGO 2009 staging. BT = brachytherapy; RT = radiation therapy.</p

Schematic figure of FGFR2 mutations identified in endometrioid endometrial tumors.

<p>Blue diamonds indicate each instance of a mutation in the Washington University School of Medicine cohort. Mutations are numbered relative to <i>FGFR2</i>b (NP_075259.2). Mutations at 6 codons (S252, P253, Y376, C383, N550, K660) comprise >90% of all mutations identified.</p

Patient Demographics and Clinicopathologic Characteristics.

<p>Patient Demographics and Clinicopathologic Characteristics.</p

Hazard ratio (HR) and 95% confidence interval (CI) for cohort of 386 Stage I/II cases.

<p>*For DFS, the multivariate model included Stage 1C, II, Grade 2 and 3.</p><p>**For OS, the multivariate model included age, FIGO Stage 1C, II, Grade 2 and Grade 3.</p>a<p>FGFR2 adjusted for KRAS in addition to covariates above.</p>b<p>KRAS adjusted for FGFR2 in addition to covariates above.</p

Hazard Ratio (HR) and 95% Confidence Interval (CI) for Cohort of 466 Endometrioid Endometrial Cancers.

<p>*For DFS, the multivariate model included Stage 1C, II, III/IV, grade 2 and 3.</p><p>**For OS, the multivariate model included age, FIGO stage 1C, II, III/IV, grade 2 and grade 3.</p>a<p>FGFR2 adjusted for KRAS in addition to covariates above.</p>b<p>KRAS adjusted for FGFR2 in addition to covariates above.</p